Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has...

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308